Target Audience
This continuing education (CE) session was planned to meet the needs of professional staff who deal with the selection and monitoring of medication(s) as part of their patient care duties, including: pharmacists, RNs, APRNs, PAs, MDs.

Activity Overview
Since the emergence of SARS-CoV-2 pandemic, the practice of pharmacy has been altered to some degree in most, if not all, facets and pharmacists have been engaged in many aspects of the pandemic response. A panel consisting of pharmacists from a wide range of practice specialties will answer audience questions regarding their experiences in the COVID-19 response including treatment algorithm development, investigational drugs, healthcare incident command response, and patient care in the emergency department, critical care, and pediatric settings.

Learning Objectives
At the conclusion of this knowledge-based CE session, participants should be able to:
1. Describe how pharmacists can be involved in healthcare incident command response to a pandemic
2. Identify medications currently being used and investigated in the treatment of COVID-19 disease
3. Discuss pharmacotherapy treatment considerations in critically ill patients with COVID-19 disease

Faculty Information - Panel

Christopher J. Arendt, PharmD
Senior Clinical Manager
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Anna S. Bartoo, PharmD
Senior Manager – Pharmacy Research
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Laura M. Dinnes, PharmD, BCPPS
Pediatric Clinical Pharmacist
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Kirstin Kooda, PharmD, BCPS, BCCCP
Emergency Medicine and Critical Care Pharmacist
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Bradley J. Peters, PharmD, BCPS, BCCCP
Emergency Medicine and Critical Care Pharmacist
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN
Faculty Information - Moderators

Lee P. Skrupky, PharmD, BCPS
Manager – Pharmacy Education
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Christina G. Rivera, PharmD, BCPS, AAHIV-P
Infectious Diseases Pharmacist
Department of Pharmacy
Mayo Clinic Hospital – Rochester, MN

Approved Provider Statement

In support of improving patient care, this activity is planned and implemented by Mayo Clinic College of Medicine and Science. Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statements

AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:
The faculty report the following relationships:

- Christopher J. Arendt, PharmD; Anna S. Bartoo, PharmD; Laura M. Dinnes, PharmD, BCPPS; Kirstin J. Kooda, PharmD, BCPS, BCCCP; Bradley J. Peters, PharmD, BCPS, BCCCP; Ryan W. Stevens, PharmD, BCIDP; Lee P. Skrupky, PharmD, BCPS; Christina G. Rivera, PharmD, BCPS, AAHIV-P
  - All declare no financial relationship(s) pertinent to this session
  - All declare off-label use of devices and medications will be discussed during this presentation, including:
    - anakindra
    - canakinumab
    - convalescent plasma
    - eculizumab
    - hydroxychloroquine
    - IVIG
    - lopinavir/ritonavir
    - remdesivir
    - sarilumab
    - tocilizumab

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session. Members include:

- Brenda Amaris
- Mary Ellen Cordes, MS, APRN, CNS, NE-BC
- Michael Huckabee, MPAS, PA-C, PhD
- Wayne Nicholson, MD, PharmD, BCPS
- Garrett Schramm, PharmD, BCPS
- Lee Skrupky, PharmD, BCPS

For additional disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee members visit ce.mayo.edu, About Us, Disclosures - or -
https://ce.mayo.edu/content/disclosures